EGFR and non-small cell lung carcinoma: The effectiveness can be shown by the fact that phase III LUMINOSITY trial is being conducted which in the future could help us evaluate further the response as well as the safety and tolerability profile factor to treat EGFR- non-squamous NSCLC.